PRESENTING FACULTY
Stephanie Christenson, MD, MAS
Associate Professor
Division of Pulmonology, Critical Care, Allergy, and Sleep Medicine
University of California, San Francisco
San Francisco, California
Gerard J. Criner, MD, FACP, FACCP
Chair and Professor
Thoracic Medicine and Surgery
Lewis Katz School of Medicine
Director, Temple Lung Center
Philadelphia, Pennsylvania
PROGRAM OVERVIEW
This enduring activity is for pulmonologists and advanced practice providers focused on COPD helps clinicians to better understand the pathophysiology of COPD—especially type 2 inflammation—and how phenotypes, biomarkers, and treatable traits can inform diagnosis and personalized treatment. It also highlights how guideline-based care, patient-centered decision-making, and multidisciplinary collaboration can improve outcomes for people living with COPD.
TARGET AUDIENCE
This educational activity is intended for pulmonologists and pulmonology advanced practice providers involved in the care of patients with COPD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the pathophysiologic mechanisms, including the role of type 2 inflammatory pathways, underlying COPD development and progression
- Incorporate disease phenotypes, biomarkers, and treatable traits into COPD diagnostic and treatment planning discussions
- Construct guideline-informed COPD treatment plans that integrate the patient perspective and multidisciplinary care
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.50 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Dr Criner receives funding in the form of:
- Grants received: National Institutes of Health-National Heart, Lung, and Blood Institute (NIH-NHLBI), GSK, Boehringer Ingelheim, Novartis, AstraZeneca, Respironics, MedImmune, Novartis, Pearl Therapeutics, PneumRx, Pulmonx, Broncus Medical, Spiration, Olympus Therapeutics, Fisher & Paykel Healthcare, Chiesi, Gilead Sciences, Pfizer, Corvus Pharmaceuticals, Lilly, Regeneron Pharmaceuticals, Genentech, Roche, Gravitas Pharma, CSA Medical, Gala Therapeutics, Galvanize Therapeutics, Nuvaira, Apreo Health
- Consultation: AstraZeneca, Nuvaira, GSK, CSA Medical, PneumRx, BTG, Mereo BioPharma, Broncus Medical, Pulmonx, GSK, Eolo Pharma, Olympus Therapeutics, Novartis, Chiesi, Medtronic, Gilead Sciences, Boehringer Ingelheim, Gala Therapeutics, Intuitive, Apreo Health
- GOLD: Board of Directors member and Science Committee member
Dr. Christenson receives funding in the form of:
- Grants received: National Institutes of Health (NIH), American Lung Association, COPD Foundation, US Department of Defense, Uniquity Bio
- Consulting or advisory board participation: Sanofi, AstraZeneca, AbbVie, Apogee Therapeutics, Genentech, Regeneron Pharmaceuticals, GSK, Verona Pharma, Amgen, Uniquity Bio/DevPro Biopharma, Kymera Therapeutics, Gilead Sciences
- Fees for nonbranded talks: Regeneron, Sanofi, AstraZeneca
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, MSN, APRN, AGACNP-BC, SCRN, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, BSc, Medical Director for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
- Melanie Grau, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 10, 2026
EXPIRATION DATE: June 10, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
